3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Pancreatic Neoplasms
24
Breast Neoplasms
13
Triple Negative Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
3
Thymoma
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Nasopharyngeal Carcinoma
2
Locally Advanced Pancreatic Cancer
2
Borderline Resectable Pancreatic Cancer
2
Biliary Tract Neoplasms
2
Advanced Pancreatic Cancer
2
Advanced Gastric Cancer
2
Uterine Cervical Neoplasms
1
Thromboembolism
1
Thoracic Neoplasms
1
Stage IV Gastric Cancer With Metastasis
1
Stage IA Pancreatic Adenocarcinoma
1
Squamous Cell Carcinoma of Lung
1
Small Cell Lung Carcinoma
1
Resectable Biliary Tract Cancer
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Ductal Adenocarcinoma
1
Muscle-Invasive Bladder Carcinoma
1
Melanoma
1
Lung Diseases
1
Locally Advanced or Metastatic Gastric Adenocarcinoma
1
Locally Advanced Cervical Carcinoma
1
Interventions
tislelizumab
1
spartalizumab
1
Nivolumab
1
Gemcitabine
1
Cisplatin
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Muscle-Invasive Bladder Carcinoma
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT04876313
2022-04-06
NURE-Combo
IRCCS San Raffaele
Phase 2
Unknown
29 enrolled